Supplementary Table 2.
Comparison of Demographic Parameters, IBD Types, Comorbid Diseases, and IBD Medications Between Patients in the Lagevrio and Control Cohorts Before and After Propensity-Score Matching
| Demographics | Before propensity-score matching |
After propensity-score matching |
||||
|---|---|---|---|---|---|---|
| Lagevrio cohort (n = 150) | Control cohort (n = 29,589) | P value | Lagevrio cohort (n = 149) | Control cohort (n = 149) | P value | |
| Age, y | 59.7 ± 16.5 | 50.3 ± 19.5 | <.0001 | 59.6 ± 16.5 | 59 ± 16.8 | .75 |
| BMI | 29.9 ± 6.09 | 29.1 ± 7.26 | <.0001 | 29.9 ± 6.11 | 30.2 ± 6.69 | .78 |
| Female gender | 100 (66%) | 17811 (60%) | .10 | 99 (66%) | 101 (67%) | .80 |
| Hispanic or Latino | 10 (6.6%) | 1391 (4.7%) | .25 | 10 (6.7%) | 10 (6.7%) | 1 |
| Race | ||||||
| White | 139 (92%) | 23825 (80%) | .0002 | 138 (92%) | 134 (89%) | .41 |
| African American | 10 (6.7%) | 3437 (11%) | .05 | 10 (6.7%) | 11 (7.3%) | .82 |
| COVID vaccine | ||||||
| BNT162b2 (Pfizer) | 10 (6.7%) | 1074 (3.6%) | .04 | 10 (6.7%) | 13 (8.7%) | .51 |
| Messenger RNA-1273 (Moderna) | 10 (6.7%) | 226 (0.7%) | <.0001 | 10 (6.7%) | 10 (6.7%) | 1 |
| Ad26.COV2.S (Johnson & Johnson) | 10 (6.7%) | 18 (0.06%) | <.0001 | 0 | 0 | N/A |
| IBD type and subtype | ||||||
| UCa | 84 (56%) | 13873 (46%) | .02 | 83 (55%) | 71 (47%) | .16 |
| Ulcerative proctitis | 15 (10%) | 2134 (7.2%) | .18 | 15 (10%) | 15 (10%) | 1 |
| Ulcerative rectosigmoiditis | 10 (6.7%) | 1491 (5%) | .36 | 10 (6.7%) | 10 (6.7%) | 1 |
| Left-sided colitis | 10 (6.7%) | 1381 (4.6%) | .24 | 10 (6.7%) | 10 (6.7%) | 1 |
| UC pancolitis | 32 (21%) | 4458 (15%) | .03 | 32 (21%) | 22 (14%) | .13 |
| CDa | 82 (54%) | 14318 (48%) | .12 | 52 (34%) | 43 (28%) | .26 |
| CD of small intestine | 30 (20%) | 5648 (19%) | .77 | 30 (20%) | 34 (22%) | .57 |
| Intestinal obstruction/stricture | 10 (6.7%) | 855 (2.8%) | .006 | 10 (6.7%) | 10 (6.7%) | 1 |
| Fistula | 10 (6.7%) | 441 (1.4%) | <.0001 | 10 (6.7%) | 10 (6.7%) | 1 |
| Abscess | 0 | 186 (0.6%) | .33 | 0 | 0 | N/A |
| CD of large intestine | 30 (20%) | 5742 (19%) | .85 | 30 (20%) | 22 (14%) | .87 |
| Intestinal obstruction/stricture | 10 (6.7%) | 367 (1.2%) | <.001 | 10 (6.7%) | 0 | .001 |
| Fistula | 10 (6.7%) | 665 (2.2%) | .0003 | 10 (6.7%) | 0 | .0013 |
| Abscess | 0 | 312 (1%) | .20 | 0 | 0 | N/A |
| CD of small and large intestine | 21 (14%) | 4404 (14%) | .76 | 21 (14%) | 31 (20%) | .1 |
| Fistula | 0 | 726 (2.4%) | .05 | 0 | 0 | N/A |
| Abscess | 0 | 279 (0.9%) | .23 | 0 | 0 | N/A |
| Small intestine resection | 0 | 10 (0.03%) | .82 | 0 | 0 | N/A |
| Total colectomy | 10 (6.6%) | 86 (0.2%) | <.0001 | 10 (6.7%) | 10 (6.7%) | 1 |
| Comorbid diseases | ||||||
| Diabetes mellitus | 52 (34%) | 7833 (26%) | .02 | 52 (34%) | 43 (28%) | .26 |
| Nicotine dependence | 22 (14%) | 6151 (20%) | .06 | 22 (14%) | 20 (13%) | .73 |
| Ischemic heart disease | 43 (28%) | 6560 (22%) | .05 | 43 (28%) | 39 (26%) | .60 |
| Chronic lower respiratory disease | 87 (58%) | 12122 (40%) | <.0001 | 86 (57%) | 86 (57%) | 1 |
| Chronic kidney disease | 51 (34%) | 6841 (23%) | .001 | 51 (34%) | 47 (31%) | .62 |
| Heart failure | 23 (15%) | 3990 (13%) | .50 | 23 (15%) | 22 (14%) | .87 |
| Medications | ||||||
| Prednisoneb | 22 (14%) | 5411 (18%) | .25 | 22 (14%) | 21 (14%) | .86 |
| Budesonideb | 10 (6.6%) | 2268 (7.6) | .64 | 10 (6.6%) | 10 (6.6%) | 1 |
| Methylprednisoloneb | 12 (8%) | 3591 (12%) | .12 | 12 (8%) | 10 (6.6%) | .65 |
| Infliximab | 15 (10%) | 3396 (11%) | .57 | 15 (10%) | 15 (10%) | 1 |
| Adalimumab | 21 (14%) | 3736 (12%) | .61 | 21 (14%) | 23 (15%) | .74 |
| Golimumab | 10 (6.6%) | 175 (0.5%) | <.0001 | 10 (6.6%) | 10 (6.6%) | 1 |
| Certolizumab | 10 (6.6%) | 405 (1.3%) | <.0001 | 10 (6.6%) | 10 (6.6%) | 1 |
| Vedolizumab | 10 (6.6%) | 1522 (5.1%) | .39 | 10 (6.6%) | 10 (6.6%) | 1 |
| Ustekinumab | 10 (6.6%) | 1375 (4.6%) | .24 | 10 (6.6%) | 10 (6.6%) | 1 |
| Tofacitinib | 10 (6.6%) | 329 (1.1%) | <.0001 | 10 (6.6%) | 10 (6.6%) | 1 |
| Azathioprine | 20 (13%) | 3132 (10%) | .27 | 20 (13%) | 22 (14%) | 1 |
| Methotrexate | 12 (8%) | 2120 (7%) | .69 | 12 (8%) | 17 (11%) | .32 |
| Mercaptopurine | 10 (6.6%) | 1437 (4.8%) | .30 | 10 (6.6%) | 10 (6.6%) | 1 |
NOTE. To maintain patient confidentiality, when numbers of events are greater than 1 but fewer than 10, TriNetX rounds up events to 10.
BMI, body mass index; CD, Crohn’s disease; COVID, coronavirus disease; IBD, inflammatory bowel disease; N/A, not applicable; UC, ulcerative colitis.
a
Total UC and CD is not 100% owing to possible overlap of International Classification of Diseases, 10th revision, Clinical Modification codes in patients
b
Medications prescribed within 6 months before prescription of Lagevrio.